therapies
We will develop novel antiviral therapies to addess an unmet medical need for treatment of immunocompromised patients.
Initial focus on niche indication with possible orphan drug designation, with low competition followed by expansion to major indications with high medical need.
Eirium AB was founded in 2012 as a spin-off company from Umeå University, Sweden. Our foundation is based on close collaborations between chemistry and virology expertise.
©2014 Eirium AB, Umeå, Sweden